Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

The KRAS G12C mutation is found in approximately 3% of all colorectal cancer cases and 1% to 2% of pancreatic adenocarcinoma ...

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer ...

HYDERABAD: VeGen Labs LLP, a biotech startup incubated at ASPIRE-TBI and ASPIRE-BioNEST, University of Hyderabad (UoH), has been awarded Rs 3.765 crore funding from the Biotechnology Industry Research ...

In patients with pancreatic ductal adenocarcinoma, KRAS G12D and G12V mutations hare associated with worse patient outcomes, ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...